New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
AviadoBio Announces Presentation of Promising Preclinical Safety and Biodistribution Data of its Gene Therapy Candidate AVB-101 for FTD-GRN at the Annual European Society of Gene and Cell Therapy Cong
-
Transfix Closes $40M Series F Funding Round Led by New Enterprise Associates and G Squared
-
Waymark Secures Additional $42M to Scale Tech-Enabled, Community-Based Care for Primary Care Providers and People Enrolled in Medicaid
-
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
-
Form SC 13D/A SYNLOGIC, INC. Filed by: New Enterprise Associates 14, L.P.
-
Mojo Vision Closes Successful New Series A Funding Round with $43.5M to Drive Micro-LED Development and Commercialization
-
Pair Eyewear Announces $75M Series C Funding Round As It Touts Revenue Growth And Enhanced Automated U.S. Manufacturing
-
AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations
-
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
-
MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
-
Form SC 13D/A Bright Health Group Inc. Filed by: New Enterprise Associates 15, L.P.
-
Non-Alcoholic Retailer Boisson Announces New CEO; Receives New Funding From Convivialité Ventures and Connect Ventures
-
Bright Health Group (BHG) Continues to Make Significant Progress Towards ACA Insurance Business Wind-Down
-
Bright Health Group Continues to Make Significant Progress Towards ACA Insurance Business Wind-Down
-
Hunt Scanlon Media to Host Private Equity and Venture Capital Recruiting Conference
-
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
-
SafeBase Acquires Fellow Y Combinator-Backed Stacksi to Fuel Its Vision for Zero-friction Security Assessments
-
OncoResponse Announces Appointment of Carol Gallagher to Board of Directors
-
Revelle Aesthetics™ Brings Cellulite Education to the Forefront in Celebration of National Cellulite Day
-
Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty cer
-
Zeal Capital Partners Welcomes Former New Enterprise Associates Healthcare Investor, Emily Zhen, as Principal
-
MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
-
Modyfi launches full public beta for AI design platform, announces $7M in seed funding led by NEA
-
Form SC 13D/A Bright Health Group Inc. Filed by: New Enterprise Associates 15, L.P.
-
Reimagined TechCrunch Disrupt 2023 Features New Stages and Return of Expanded Startup Battlefield Competition
-
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
-
Ikena Oncology (IKNA) Acquires Pionyr Immunotherapeutics in All-Stock Transaction
-
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
-
Bright Health Group Secures Financing to Support Operations Pending the Expected Close of California Medicare Advantage Business Sale
-
Insurtech Startup Functional Finance Raises $8 Million to Further Expand Operational Efficiency for the Insurance Industry
-
Nexo Therapeutics Launches With $60 Million Series A Financing
-
Form 4 Sagimet Biosciences Inc. For: Jul 18 Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
TEDCO Announces FY24 Board of Directors
-
Gossamer Bio Inc. (GOSS) Announces $212M Private Placement Financing
-
Gossamer Bio Announces $212 Million Private Placement Financing
-
Savara (SVRA) Prices 21M Share Offering at $3/sh
-
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
NEA Welcomes Mark Hawkins as Venture Partner
-
First U.S. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study
-
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
-
Form SC 13D/A MINERVA SURGICAL INC Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Aigen Unveils the World's First AI-Driven, Solar-Powered, Agricultural Robotics Service
-
Mirati Therapeutics (MRTX) Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
-
Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
-
Form SC 13D/A Mirum Pharmaceuticals, Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A Arcellx, Inc. Filed by: New Enterprise Associates 15, L.P.
-
AvoMD Raises $5M to Combat Clinician Burnout With No-Code Clinical App Building Platform
-
Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics
-
Form 4 Mirum Pharmaceuticals, For: Jun 13 Filed by: New Enterprise Associates 16, L.P.
-
Kyber Knight Capital Launches With a $120 Million Inaugural Fund

